报价延迟最少15分钟:2026/04/18 01:25 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.98 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
1.43/-0.87
|
|
企业价值
323.30M
|
| 资产负债 |
|
每股账面净值
0.41
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
42.17M
|
|
每股收益
1.41
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems. |
